Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis

Biomaterials

Volumn 32, Issue 33, 2011, Pages 8548-8554

  Werner, Michael E ^a   Karve, Shrirang ^a   Sukumar, Rohit ^a   Cummings, Natalie D ^a   Copp, Jonathan A ^a   Chen, Ronald C ^a   Zhang, Tian ^b   Wang, Andrew Z ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoradiotherapy; Chemotherapy; Folate targeted nanoparticles; Molecular targeted nanoparticles; Nanomedicine; Nanoparticle

Indexed keywords

CHARACTERIZATION STUDIES; CHEMORADIOTHERAPY; FOLATE RECEPTOR; IN-VITRO; IN-VIVO; INTRAPERITONEAL; MONODISPERSED PARTICLES; NANOMEDICINES; NON-TARGETED; OVARIAN CANCERS; PACLITAXEL; TARGETED NANOPARTICLE; TUMOR CELLS;

CHEMOTHERAPY; DISEASES; LIGANDS; MEDICAL NANOTECHNOLOGY; PATHOLOGY; RADIOTHERAPY;

NANOPARTICLES;

FOLATE RECEPTOR; FOLIC ACID; PACLITAXEL; RADIOISOTOPE; YTTRIUM 90;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CANCER THERAPY; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; COMBINED MODALITY THERAPY; FEMALE; FOLIC ACID; HUMANS; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS;

EID: 80052966711     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.07.067     Document Type: Article

References (13)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Cannistra S.A. Cancer of the ovary. N Engl J Med 1993, 329:1550-1559.
3. Lu Z., Wang J., Wientjes M.G., Au J.L. Intraperitoneal therapy for peritoneal cancer. Future Oncol 2010, 6:1625-1641.
4. Soper J.T., Wilkinson R.H., Bandy L.C., Clarke-Pearson D.L., Creasman W.T. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging. Am J Obstet Gynecol 1987, 156:1153-1158.
5. Goodman A., Bornstein L., Ball H., Smith D.M., Bankoff M. Chromic phosphate therapy in carcinoma of the ovary. J Am Coll Surg 1994, 179:401-406.
6. Jelovac D., Armstrong D.K. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011, 61(3):183-203.
7. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34-43.
8. Wang A.Z., Gu F., Zhang L., Chan J.M., Radovic-Moreno A., Shaikh M.R., et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther 2008, 8:1063-1070.
9. Gisselbrecht C., Vose J., Nademanee A., Gianni A.M., Nagler A. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. Oncologist 2009, 14(2):41-51.
10. Yap T.A., Carden C.P., Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009, 9:167-181.
11. Zhang L., Chan J.M., Gu F.X., Rhee J.W., Wang A.Z., Radovic-Moreno A.F., et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2008, 2:1696-1702.
12. Wang A.Z., Yuet K., Zhang L., Gu F.X., Huynh-Le M., Radovic-Moreno A.F., et al. ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomedicine (Lond) 2010, 5(3):361-368.
13. Seiwert T.Y., Salama J.K., Vokes E.E. The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 2007, 4:86-100.